GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Cash, Cash Equivalents, Marketable Securities

enVVeno Medical (enVVeno Medical) Cash, Cash Equivalents, Marketable Securities : $42.94 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Cash, Cash Equivalents, Marketable Securities?

enVVeno Medical's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 ($25.70 Mil) to Dec. 2023 ($46.41 Mil) but then stayed the same from Dec. 2023 ($46.41 Mil) to Mar. 2024 ($42.94 Mil).

enVVeno Medical's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($54.73 Mil) to Dec. 2022 ($39.04 Mil) but then increased from Dec. 2022 ($39.04 Mil) to Dec. 2023 ($46.41 Mil).


enVVeno Medical Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for enVVeno Medical's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical Cash, Cash Equivalents, Marketable Securities Chart

enVVeno Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 1.31 9.34 54.73 39.04 46.41

enVVeno Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.21 29.76 25.70 46.41 42.94

enVVeno Medical Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


enVVeno Medical  (NAS:NVNO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


enVVeno Medical Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


enVVeno Medical (enVVeno Medical) Business Description

Industry
Traded in Other Exchanges
Address
70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Executives
Hamed Alavi officer: Chief Technology Officer ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman director, officer: CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis director 2 GOODYEAR, IRVINE CA 92618
Robert Gray director 70 DOPPLER, IRVINE CA 92618
Marc H. Glickman officer: See Remarks 70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a. 10 percent owner 13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn officer: Chief Financial Officer 70 DOPPLER, IRVINE CA 92618
Marcus W. Robins director C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin officer: Chief Financial Officer 9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd 10 percent owner P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle director 70 DOPPLER, IRVINE CA 92618
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Susan Montoya officer: See Remarks 70 DOPPLER, IRVINE CA 92618